References
- Radack K, Deck CC. Are oral decongestants safe in hypertension? An evaluation of the evidence and a framework for assessing clinical trials. Ann Allergy 1986: 56(5): 396–401
- Kroenke K, Omori DM, Simmons JO, et al. The safety of phenylpropanolamine in patients with stable hypertension. Ann Intern Med 1989: 111(12): 1043–4
Reference
- Bradley J, Kallail K, Dorsch J, et al. The effect of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial. J Am Board Fam Pract 1991: 4: 201–6
References
- Giardina EG, Bigger JT Jr. Antiarrhythmic effect of imipramine hydrochloride in patients with ventricular premature complexes without psychological depression. Am J Cardiol 1982: 50(1): 172–9
- Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity and tricyclic antidepressants. Biomed Pharmacother 1987: 41(7): 377–82
- Veith RC, Raskind MA, Caldwell JH, et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982: 306(16): 954–9
- Connolly SJ, Mitchell LB, Swerdlow CD, et al. Clinical efficacy and electrophysiology of imipramine for ventricular tachycardia. Am J Cardiol 1984: 53(4): 516–21
- Moir DC, Cornwell WB, Dingwall-Fordyce I, et al. Cardiotoxicity of amitriptyline. Lancet 1972: 2(777): 561–4
- Moir DC, Dingwall-Fordyce I, Weir RD. Medicines evaluation and monitoring group: a follow-up study of cardiac patients receiving amitriptyline. Eur J Clin Pharmacol 1973: 6(2): 98–101
- Stanton MS, Prystowsky EN, Fineberg NS, et al. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation. J Am Coll Cardiol 1989: 14(1): 209–15